Biopharmaceutical company Oakrum Pharma LLC revealed on Monday the launch of an agreement to develop and manufacture two prescription generic pharmaceutical products to be commercialised in the US under the Oakrum label.
The company said it has signed the product development and commercialisation partnership with Biophore India Pharmaceuticals Pvt Ltd, a pharmaceutical company.
Both the prescription generic pharmaceutical products are expected to be sold through the specialty distribution market channel.
For the 12-month period ending 31 December 2018, the total market for the products in the US exceeded USD150m in aggregate sales, according to Bloomberg data.
Dr Reddy's Laboratories unveils Pregabalin Capsules in the US market
Baxter Wins US FDA Approval of Myxredlin, The First and Only Ready-To-Use Insulin for IV Infusion
Novadoz Pharmaceuticals awarded US FDA approval for generic Pregabalin capsules
Dr. Reddy's Laboratories Launches Ramelteon Tablets, in the US Market
US FDA approves first generic Lyrica for mutliple indications
Rising Pharmaceuticals launches and begins shipment of generic version of Lyrica in US